COMMA Investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMMA trial - Granger, CB; Mahaffey, KW; Weaver, WD (Circulation, 2003)
et al.